early stage favourable disease
Treatment strategies of early stage Hodgkin lymphoma (HL) have changed during recent years. Until recently, extended field (EF) irradiation has been considered the standard treatment. However, due to the recognition of the high relapse rate and the fatal long-term effects, EF radiotherapy (radiation to initially involved and adjacent lymph node areas) is now being abandoned by most study groups. Instead, for favourable early stage disease, short duration chemotherapy for control of occult lesions is combined with involved field irradiation (IF-RT; restricted only to initially involved lymph node areas). Most groups and centres give four courses of adriamycin, bleomycin, vinblastine, dacarbazine (ABVD) followed by IF-RT [30-35 gray (Gy)] [1] .
Many of the ongoing and recently completed studies were developed in an attempt to reduce the long-term complications of treatment without increasing mortality from HL. These include studies that evaluate reduction of radiation dose or field size; combined modality treatment in an attempt to identify the optimal chemotherapy regimen; the optimal number of cycles of chemotherapy; and to determine the optimal radiation volume and dose when combined with chemotherapy. Table 1 summarizes the most prominent ongoing or recently terminated international trials [2, 3] .
early stage unfavourable disease
It is generally accepted that early stage unfavourable (intermediate) HL patients (clinical stage/performance status (CS/PS) I and II with certain risk factors; Table 2 ), qualify for combined chemotherapy and radiotherapy. However, the prognostic impact of a single risk factor, the optimal chemotherapy regimen, the number of chemotherapy cycles, the radiation-field sizes, and the dosage of radiation within these fields are subjects of ongoing studies and continuing debates.
trials to identify the best chemotherapy regimen
Based mainly on results of trials in advanced HL, ABVD has become the standard regimen for CS I-II patients. Three current trials analyse combined modality protocols comparing ABVD with more intense, novel regimens. Both the EORTC H9U and the GHSG HD11 studies are comparing 4 cycles of ABVD with 4 cycles of BEACOPP baseline (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) and radiotherapy is limited to IF at a dose of 20 or 30 Gy, respectively. The ECOG 2496 trial compares 6 cycles of ABVD to 12 weeks of Stanford V, followed by radiotherapy [4] . Most of these studies are ongoing or have been recently closed. The data are generally not yet available in a final report.
radiation field and dose
In preceding studies, the GHSG randomized responding patients in early unfavourable (intermediate) stages to either 40 or 20 Gy EF + 20 Gy IF (HD1) with no outcome difference. In the follow-up trial (HD5), patients received 30 Gy EF + 10 Gy on bulky sites. These trials demonstrated that radiation dose in the EF can safely be reduced to at least 30 Gy (with 10 Gy on bulky tumours) when given after 2 cycles of alternating cyclophosphamide, vincristine, procarbazine and prednisone (COPP/ABVD) [5] .
The question as to whether radiation fields can be reduced to the involved sites after adequate chemotherapy was sufficiently answered by the Milan trial (Table 1) , which did not differentiate between favourable and unfavourable early HL patients, and the HD 8 trial of the GHSG (Table 3) . This trial compared radiotherapy of 30 Gy EF + 10 Gy to bulk (>5 cm) and 30 Gy IF + 10 Gy to bulk after 2 alternating cycles of COPP/ABVD. 1204 patients were randomized between 1993 and 1998 and 1064 patients were evaluable. The median observation time was 54 months. The overall survival (OS) for all eligible patients was 91% and freedom from treatment failure (FFTF) was 83%. Comparisons of both arms showed similar rates of FFTF (85.8 and 84.2%) and OS at 5 years (90.8 and 92.4%). There were also no significant differences between the 2 arms in terms of complete remission (98.5 and 97.2%), progressive disease (0.8 and 1.9%), relapse (6.4 and 7.7%), death (8.1 and 6.4%), and secondary cancers (4.5 and 2.8%). In contrast, acute side effects including leukopenia, thrombocytopenia, nausea, and gastrointestinal and pharyngeal toxicity were more frequent in the EF arm. The Milan trial and the GHSG HD8 trial comparing 30 Gy radiotherapy in EF or IF technique define a new standard of treatment for patients in early unfavourable stage HL, i.e. 4 cycles of effective chemotherapy followed by IF radiotherapy [6] .
The shortcoming of this strategy, however, is that 5% of those patients with intermediate stage will suffer from symposium article progressive disease while on ABVD-like chemotherapy and another 15% will relapse within the following 5 years. Despite this fact, based mainly on trials in advanced HL and its reduced acute and long-term toxicities in comparison with protocols including alkylating agents, ABVD has become the standard regimen used in patients with unfavourable (intermediate) CS I-II disease.
The recently closed HD11 trial of the GHSG compared the efficacy of two different chemotherapy regimens: 4 ABVD versus 4 BEACOPP baseline, to test whether the doseequivalent but time intensified BEACOPP baseline regimen would decrease the still unsatisfactory 10-15% relapse and progression rate after 4 ABVD in this unfavourable prognostic setting. The fifth interim analysis of this study was done in October 2005 and included 1300 patients. After a median observation time of more than 40 months the FFTF rate for the total group was 87% (at 3 years) and the OS rate was 96% (at 3 years). There was no difference between the 4 ABVD arm and the 4 BEACOPP baseline arm, nor for the comparison between 20 and 30 Gy IF-RT.
In January 2003 the GHSG has started the HD14 trial, and in January 2007 1140 patients were already recruited. This trial compares 2 courses of escalated BEACOPP, followed by 2 courses of ABVD versus 4 ABVD courses, in both arms supported by 30 Gy IF-RT. In the second interim analysis at 18 months with 450 evaluable patients for the pooled arms the FFTF rate was 93% and the OS rate was 100%. There were 2 deaths, 8 progressions and 12 relapses, 5 secondary cancers: 2 Non-Hodgkin's lymphomas (NHLs) and 3 solid tumours. Two large randomized trials are currently evaluating whether 4 cycles of combination therapy are equally effective compared with 6 cycles of combination therapy.
The EORTC H8U study [7] randomized patients to combined modality treatment with either IF or subtotal nodal irradiation (STLI) and 4 or 6 cycles of mechlorethamine, vincristine, procarbazine and prednisone (MOPP/ABV): neither relapse-free survival nor OS differed significantly among the 3 groups.
The EORTC H9U trial randomized patients to 4 or 6 cycles of ABVD (or 4 cycles of BEACOPP). At the first interim analysis in October 2002, a freedom from progression (FFP) rate of 90% (without arm comparison) was found.
The National Cancer Institute of Canada (NCI-C) HD6 trial evaluated HL patients in stages I+II with favourable and unfavourable disease, but excluded patients with a large mediastinal mass (LMM) or bulky disease (>10 cm). Patients were randomized to receive combined modality therapy with 2 cycles of ABVD followed by irradiation (an extended mantle plus splenic irradiation or mantle plus para-aortic and splenic irradiation) or 4-6 cycles of ABVD alone (depending upon the rapidity of response). The first analysis of the data showed a significant superiority for progression-free survival (PFS) for the combination therapy while the OS at the time point of about 4 years showed no significant difference. This trial, although biased by the nowadays outdated use of extended/ subtotal nodal irradiation, will help to answer the question for which subgroup of patients in this setting chemotherapy without radiation suffices.
advanced stage disease

ABVD: the second pioneer combination
In 1975, Bonadonna and colleagues introduced the ABVD regimen [8] in an attempt to develop a regimen for patients whose disease had recurred after MOPP. The Milan group started to compare MOPP and ABVD, using 3 cycles of each drug combination, followed by EF irradiation and 3 additional cycles of the same chemotherapy. This comparison demonstrated a significant superiority for ABVD with FFP rates of 63% for MOPP versus 81% for ABVD. Since both regimens were highly active and had no overlapping toxicities, it was therefore consequent to test MOPP and ABVD in various combinations to further increase cure rates.
hybrid regimens
Investigators in Vancouver [9] and Milan [10] independently designed two hybrids of MOPP and ABVD in order to test the Goldie-Coldman hypothesis prospectively.
The NCI-C compared the MOPP-ABV hybrid with alternating MOPP/ABVD in patients with stage IIIB or IV HL. At 5 years there was no significant difference in the OS rates between both arms; however, the hybrid regimen was associated with higher haematological and non-haematological toxicities.
Subsequently, large multi-centre trials were started in the USA and Europe to compare MOPP/ABV hybrid versus alternating MOPP/ABVD and sequential MOPP/ABVD. These multi-centre trials demonstrated that MOPP/ABV hybrid was equally effective as alternating MOPP/ABVD, but more effective than sequential MOPP/ABVD [11] .
As a conclusion to the sequence of these comparative trials, first the CALGB, as reported by Canellos et al. and then later the North American Intergroup, as reported by Duggan et al., have addressed the important question of whether the inclusion of MOPP in the conventional setting and scheduling add therapeutic benefit to ABVD or merely enhances toxicity [12] . The authors concluded that ABVD alone is equally effective as MOPP/ABV hybrid but less toxic, and all combinations are more effective than MOPP alone. In addition, ABVD alone has the advantage of less acute toxicity, especially no sterility and few or no secondary acute myeloid leukaemias/myelodysplastic syndromes (AML/MDS). But one has to keep in mind the cardiotoxicity due to doxorubicin and pulmonary side effects due to bleomycin after the application of 6-8 courses ABVD, even more if one adds consolidation radiotherapy. However, at present, it is internationally accepted that ABVD should be the standard regimen against which all experimental drug combinations should be tested.
new chemotherapy regimens
Stanford V, a 7-drug regimen, was developed as a shortduration, reduced-toxicity program including doxorubicin, vinblastine, mechlorethamine, bleomycin, vincristine, etoposide and prednisone. The program was applied weekly over of 12 weeks. Consolidation radiotherapy to sites of initial bulky disease was employed. In this phase II trial, 142 patients were recruited. The estimated 5-year FFP was 89% and the OS was 96% at a median observation time of 5.4 years in this single centre study [13] . An intergroup trial testing Stanford V versus ABVD versus MOPPEBVCAD has recently been terminated for patients with advanced HL [14] . Stanford V was shown to be inferior in terms of response rate (76 versus 89 versus 94%) and PFS (73 versus 85 versus 94%). Only a minor fraction of patients received consolidation radiotherapy. MOPPEBVCAD was the most myelotoxic regimen leading to dose reduction in a substantial proportion of patients.
Similarly, the Manchester group developed an abbreviated, 11-week chemotherapy program, vincristine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin (VAPEC-B). In a randomized trial VAPEC-B and the hybrid ChlVPP/EVA (Table 4) were compared with radiotherapy to previous bulky disease or residual disease [15] . This study was stopped after 26 months due to a 3-fold increase in the rate of progression after VAPEC-B. After a median follow up time of 4.9 years FFP, event-free survival (EFS) and OS were significantly better with ChlVPP/EVA than with VAPEC-B (FFP: 82 versus 62%; EFS: 78 versus 58%; OS: 89 versus 79%, respectively). An overview of different chemotherapy regimen used for advanced stage HL is given in Table 5 .
regimens with increased dose-intensity and dose-density
In 1992, the GHSG designed the BEACOPP regimen that used similar drugs as in the COPP/ABVD regimen, excluding vinblastine and dacarbazin and adding etoposide, trying to increase efficacy by two modifications: dose-density and dose-intensity by squeezing the drug application to 14, respectively 9 days and recycle already on day 21 or respectively day 15. After dose-finding and feasibility studies, the GHSG designed a 3-arm study, the HD9 trial, comparing COPP/ABVD, BEACOPP baseline and escalated BEACOPP in patients with advanced HL. Radiotherapy was prescribed for bulky disease at diagnosis (30 Gy) or for residual disease (40 Gy) after 8 cycles of chemotherapy and about two-thirds of patients received consolidation radiotherapy. In the final analysis in June 2001, 1201 patients were evaluated. There was a significant difference in FFTF in favour for escalated BEACOPP (87%) compared with baseline BEACOPP (76%) and COPP/ABVD (69%) at 5 years median observation time. A major difference was also observed in the rate of primary progressive disease during initial therapy which was significantly lower with escalated BEACOPP (2%) versus baseline BEACOPP (8%) and COPP/ ABVD (12%) (P < 0.001). The OS rates for COPP/ABVD were 83%, for baseline BEACOPP 88% and for escalated BEACOPP 91%. The survival differences were highly significant in the global test (P < 0.002), and the survival difference between COPP/ABVD and escalated BEACOPP again were significantly different (P < 0.002). As expected, escalated BEACOPP was associated with greater haematological toxicity including a higher number of red blood cell and platelet transfusions. Second malignancies, including AML, possibly related to etoposide, were reported (AML/MDS: escalated BEACOPP n = 9, baseline BEACOPP n = 4, COPP/ABVD n = 1). However, the total rate of secondary cancers was highest in the COPP/ABVD arm with 4.2% compared with 3.4% in the escalated BEACOPP arm. The death rates at 5 years, including all acute and late causes of deaths, were 18.8% in the COPP/ABVD arm (49/260), 13% in the baseline BECOPP (61/469) and 8.6% in the escalated BEACOPP arm (40/460). That means that 10 more patients out of 100 died in the COPP/ABVD arm [16] .
In the most recent report, which included 1186 evaluable patients with median follow-ups of 7 years, the FFTF was 67% in the COPP/ABVD group, 75% in the baseline BEACOPP group, and 85% in the escalated BEACOPP group [17] .
The induction-failure rates were 25, 12 and 4%. OS rates were 79, 84 and 90% for COPP/ABVD, baseline BEACOPP and escalated BEACOPP, respectively, with the difference between COPP/ABVD and escalated BEACOPP being significant (P < 0.002). While the two BEACOPP regimens were superior to COPP/ABVD in all prognostic groups, the most pronounced differences were in the high-risk group of patients with 4-7 adverse factors according to the International Prognostic Score (Table 6, Figure 1 and 2) .
The next trial of the GHSG, HD12, assigned patients to treatment with 8 cycles escalated BEACOPP or 4 cycles escalated BEACOPP plus 4 cycles baseline BEACOPP baseline. Following chemotherapy, patients were randomized to receive 30 Gy irradiation to initial bulky or residual disease, versus no further therapy. After a median follow-up of 30 months with 908 evaluable patients, FFTF and OS for the whole cohort were 88 and 94%, respectively. For the group getting 4 escalated BEACOPP baseline + 4 baseline BEACOPP, FFTF was 88 and OS 94% respectively; for the patient cohort getting 8 escalated BEACOPP, FFTF was 90 and OS 96%. There were no statistical differences between the two different treatment arms for either outcome measure and the toxicity profile was similar to that seen in the HD9 trial [17] .
It is noteworthy, however, that at this moment around 2500 patients in advanced stage of HL have been treated with escalated BEACOPP and have reached at a median observation time between 4 and 9 years. The total rate of AML/MDS is 0.9%, the FFTF rate is 88% and the OS rate is >90%.
The number of patients treated with consolidation radiation decreased from 65% in HD9 to 35% in HD12, and now with the help of 2-[(18)F]Fluoro-2-deoxy-_D-glucose positron emission tomography (FDG-PET) after 6-8 cycles of escalated BEACOPP or the BEACOPP-14 variant, radiation is only given to residual PET positive masses >2.5 cm, and hence the number of patients treated with IF-RT (30 Gy) is <20%.
Experience with the toxicity of the escalated BEACOPP regimen, especially the risk for AML/MDS, led to the development of a BEACOPP variant by the GHSG, in which the drug dosage and timing of administration was calculated to achieve the same efficacy with reduced toxicity, according to the dose model of Hasenclever [18] . The result was a time-intensified baseline BEACOPP regimen given at 14-day intervals, facilitated by the use of granulocyte-colony stimulating factor (G-CSF), BEACOPP-14 (Table 4) . the 14-day variant of the BEACOPP-21 regimen: the BEACOPP-14
Increase in dose intensity can by obtained by two means: (i) increasing the dosage in the same time frame (dose-intensity), or (ii) shortening the intervals between the treatment courses and shortening the time scale in which drugs are applied (dose-density).
The experiences with the high efficacy but also increased toxicity of the escalated BEACOPP principle (given in 21-day intervals) led to a BEACOPP variant, in which the drug dosage and time architecture according to the effective dose model of Hasenclever would accomplish the same efficacy, but reduced toxicity, especially concerning the rate of AML/MDS. The result was the construction of a time intensified baseline BEACOPP regimen given in 14-day intervals, applied with the help of G-CSF support for advanced HL (BEACOPP-14) (Table 4) .
From July 1997 to March 2000, the GHSG tested the feasibility, toxicity and efficacy in 99 patients in stage IIB with LMM/extranodal disease (23%), stage III/IV (77%) in a multicentre pilot study in 32 centres. The final analysis with 94 evaluable patients was performed in August 2002 [19] . In this study, 91% of the 94 patients received 8 cycles, 77% were given within 16 days, and 94% were given within 22 days; 70% of the patients were treated with consolidation radiotherapy. Seven patients with initial bulky disease were not irradiated. Eighty eight patients (94%) achieved a complete response (CR) while only four patients had progressive disease. With a median follow-up of 34 months, five patients relapsed, only one high-grade NHL developed, three patients died, one due to toxicity and two had progressive disease. The estimated FFTF was 90% and the OS 97% at 34 months median observation time. Acute haematological toxicity was moderate, ranging between that of the 21-day variants of BEACOPP (escalated and A similar approach with a potentially more active chemotherapy, BEACOPP, was performed by the GHSG within the HD12 study. In this trial, patients were randomized to 8 cycles of escalated BEACOPP or 4 cycles escalated BEACOPP + 4 cycles of baseline BEACOPP, followed by either radiotherapy to initial bulky and residual disease or no further treatment. The third interim analysis, in March 2003, with 908 patients after a median observation time of >24 months showed an FFTF of 90% and an OS of 94% with a similar toxicity as described in the HD9 trial, but a reduced number of AML/ MDS (0.6%). The comparison between the radiotherapy and the non-radiotherapy arm showed no difference, while 13% of patients in the non-radiotherapy arm were assigned by a review panel to receive 30 Gy radiation due to either minor response or residual disease >1.5 cm.
In the EORTC #20884 trial, patients with advanced stage HL achieving CR after initial 6-8 cycles of MOPP/ABV were randomly assigned to receive either IF-RT (24 Gy to all initially involved nodal areas, [16] [17] [18] [19] [20] [21] [22] [23] [24] Gy to all initially involved extranodal sites) or no further treatment. Those with partial response (PR) after chemotherapy were treated with 30 Gy to nodal areas and 18-24 Gy to extranodal areas. Of all 739 patients included, 172 received IF-RT, 161 received no further treatment, and 227 patients with PR were treated with radiotherapy. The 5-year EFS and OS rates were 84 and 91% for patients with no further treatment and 79 and 85% in the group assigned to IF-RT, respectively. Among the patients with PR after chemotherapy, the 5-year EFS rate was 79% and the OS was 87% [20] .
In the ongoing HD15 trial, the GHSG compares 8 cycles of escalated BEACOPP to 6 courses of escalated BEACOPP and 8 courses of BEACOPP-14 in patients with advanced stages of HL. In this trial radiotherapy is given only to PET positive residual tumours.
future strategies for advanced stages of hl
The aim of any modern treatment strategy in patients with advanced HL is to maintain the good results with current therapies, reaching cure rates of >85% but reduce the still too high acute and long-term toxicity.
Two internationally accepted and generally applied strategies are tested at the moment in ongoing or anticipated clinical trials: (i) risk adaptation using the International Prognostic Score (IPS), described by Hasenclever and Diehl; and (ii) response adaption using the FDG-PET to predict early response as a rather reliable indicator of prognosis.
The GHSG will start this year the HD18 trial in the sixth generation of Hodgkin studies during the last 30 years. This trial will use a response-adapted approach by tailoring therapy intensity after 2 courses of escalated BEACOPP with either continuation in the PET-positive patients with another 4-6 courses of escalated BEACOPP or reduce the intensity in the PET-negative patients and add just another 2 courses of escalated BEACOPP with no consolidation radiation to test the validity of PET scan.
IPS is still the internationally most accepted and used risk factor score for advanced HL. Many groups work intensively to find new biologic or gene expression profiling markers for the identification of risk groups in advanced HL. The results are curiously awaited.
The pivotal international study headed by the EORTC comparing 8 ABVD versus 4 escalated BEACOPP + 4 baseline BEACOPP in advanced HL patients will add valid information about the feasibility, toxicity, and the equality or superiority of the regimen in question.
Although there are no randomized studies comparing ABVD versus COPP/ABVD, one can assume that both regimen have similar efficacy in advanced HL. Therefore it seems justified to take the results with COPP/ABVD in analogy to ABVD.
do we need consolidative radiation?
The recently published paper by the EORTC [20] demonstrated that after reaching a CR after 8 cycles of effective chemotherapy, patients with advanced HL patients do not benefit from additive radiotherapy.
Having said that, 80% of the secondary AML/MDS in this study were seen in the radiotherapy arm. PR patients, however, showed a benefit from complementary radiation and fared as good as the primary CR patients.
Furthermore, the GHSG HD12 study has demonstrated that after 8 cycles of chemotherapy there was no difference between the radiotherapy or non-radiotherapy arms in an intention-totreat analysis.
There might be a risk group, however, which needs radiotherapy for elimination of the last tumour cells. This question is addressed in the HD15 trial of the GHSG, where only patients with PET-positive residual tumours are treated with 30 Gy radiation.
Therefore, consolidative radiotherapy should only be given to HL patients that only reached a PR after 6-8 courses of anthracyclin-containing chemotherapy (e.g. ABVD) or have a minor response (<70%) with residual nodal lesions. Using the new dose-and time-intensified regimen (e.g. escalated BEACOPP) for advanced HL, it seems that only a minority (<20%) of patients need consolidative radiotherapy to residual lesions of >2.5 cm. PET imaging might help to discriminate between scar and vital tumour tissue in residual lesions.
